Loading...

Neurology

Division Photo

Division of Neurology

First Row: J. Vannest, B. Wong, M. Kabbouche, D. Morita, T. Arthur, T. deGrauw, D. Gilbert; Second Row: T. Glauser, D. Krueger, A. Byars, K. Agricola; Third Row: I. Rybalsky, S. LeCates, D. Rose, J. Xiang, K. Wesselkamper; Fourth Row: C. Molloy, B. Hallinan, S. Monahan, C. Vorhees, M. Williams, A. Hershey; Fifth Row: M. Schapiro, P. Vaughan, K. Holland-Bouley, D. Franz, K. Lee

Division Data Summary
Research and Training Details
Number of Faculty24
Number of Joint Appointment Faculty2
Number of Research Fellows5
Number of Research Students3
Number of Support Personnel129
Direct Annual Grant Support $6,678,519
Direct Annual Industry Support $286,826
Peer Reviewed Publications43
Clinical Activities and Training
Number of Clinical Staff1
Number of Clinical Fellows11
Inpatient Encounters3,568
Outpatient Encounters16,028

Faculty Members

Antonius DeGrauw, MD, PhD,  Professor ; Director Neurology Division
Research Interests: neurodevelopment, mitochondrial disorders
Todd Arthur, MD,  Assistant Professor Clinical
Research Interests: brain concussion
Anna W Byars, PhD,  Associate Professor Clinical
Research Interests: cognitive effects of epilepsy
Madeline Chadehumbe, MD,  Instructor
Research Interests: neuromuscular disorders
David Franz, MD,  Professor Clinical ; Director Tuberous Sclerosis program
Research Interests: tuberous sclerosis
Donald Gilbert, MD,  Associate Professor Clinical ; Director Movement Disorders program
Research Interests: Tourette syndrome, Transcranial Magnetic Stimulation (TMS)
Tracy A Glauser, MD,  Professor Clinical ; Director Comprehensive Epilepsy program
Research Interests: epilepsy, pharmacology
Barbara Hallinan, MD,  Assistant Professor Clinical
Research Interests: CSF steroid profiles
Andrew Hershey, MD,  Professor Clinical ; Director Headache Center
Research Interests: migraine, blood genomics
Katherine Holland-Bouley, MD, PhD,  Assistant Professor Clinical
Research Interests: ion channels and epilepsy
Marielle A Kabbouche, MD,  Assistant Professor Clinical
Research Interests: migraine
Darcy Krueger, MD,  Assistant Professor Clinical
Research Interests: Tuberous Sclerosis
Ki Lee, MD,  Associate Professor Clinical ; Director EEG lab, EMU
Research Interests: Epilepsy surgery
Diego Morita, MD,  Assistant Professor Clinical
Research Interests: epilepsy, pharmacology
Tonya Phillips, MD,  Associate Professor Clinical
Research Interests: neonatal seizures
Douglas Rose, MD,  Professor Clinical ; Director MEG lab
Research Interests: Magneto-EncepaloGraphy (MEG)
Mark Schapiro, MD,  Professor Clinical ; Director Neurology Residency program
Research Interests: neurodevelopmental disorders
Mary Sutton, MD,  Assistant Professor Clinical
Research Interests: neuro-oncology
Jennifer Vannest, PhD,  Research Assistant Professor
Research Interests: speech and language development
Charles Vorhees, PhD,  Professor ; Director Animal Neurobehavior Core
Research Interests: drugs/toxicants and brain development
Kristen Wesselkamper, MD,  Assistant Professor Clinical
Research Interests: improvement science
Michael Williams, PhD,  Research Associate Professor
Research Interests: drugs/toxicants and brain development
Brenda Wong, MD,  Associate Professor Clinical ; Director Neuromuscular program
Research Interests: Duchenne's Muscular Dystrophy, Spinal Muscular Atrophy
Jing Xiang, MD, PhD,  Research Associate Professor ; Director MEG Research program
Research Interests: MEG

Clinical Staff Members

  • Tina Narayan, MD

Trainees

  • Shannon Standridge, DO,  PGYVI,  Kansas City University
  • Marc DiSabella, DO,  PGY-V,  Cooper University Hospital
  • Pierre Fequiere, MD,  PGY-V,  Long Island College Hospital
  • Steve Wu, MD,  PGY-V,  VanderBilt University
  • James Collins, MD,  PGY-IV,  University of Cincinnati
  • Sarah Hopkins, MD,  PGY-IV,  University of Arkansas
  • Laurel Malinowski, MD,  PGY-IV,  University of Wisconsin
  • Alice Lawrence, MD,  PGYIII,  Milton S. Hershey Medical Center
  • Cameron Thomas, MD,  PGYIII,  University of Colorado
  • Shawn Aylward, MD,  PGYIII,  Southern Illinois University
  • Keith Ridel, MD,  PGYIII,  University of Cincinnati

Significant Accomplishments in FY08

 Epilepsy Program

The Children’s Comprehensive Epilepsy Program is a nationally recognized leader in pediatric epilepsy with strengths in integrated multidisciplinary comprehensive clinical care, cutting edge clinical and basic research and patient education. The four major areas of focus include epilepsy pharmacology, epilepsy surgery, multimodality (MRI, fMRI, MEG) epilepsy imaging, and basic neuroscience. The pharmacology group (Drs. Glauser, Morita, Holland) aims to personalize care for children with new onset epilepsy by integrating multidisciplinary care, clinical research and patient education. The major research activities of this group include examination of the role of drug-gene interactions on the inter-individual variation in antiepileptic drug clinical response, laboratory studies of the functional significance of the genetic variations found, and study of parental adherence to prescribed medication regimens. Gene-drug interactions include research on the impact of variation in genes coding for drug metabolizing enzymes, drug transporters and drug receptors on clinical response to antiepileptic medications (pharmacogenetics) along with the impact of antiepileptic medications on gene expression (pharmacogenomics). The pharmacogenetics research is funded through an NIH U01 that is based at CCHMC and includes 31 other centers. The trial is a double blind, randomized, comparison trial of three antiepileptic medications focused on identifying the optimal initial therapy for children with absence epilepsy. The study is also designed to identify pharmacokinetic, pharmacodynamic, and pharmacogenetic factors that impact upon response to therapy. This landmark study has completed enrollment and will be announcing its results at the end of 2008.

The epilepsy surgery program, led by Drs. Lee and Mangano are undergoing a major expansion and expect to become a national leader in the surgical evaluation and management of children with treatment resistant epilepsy. The program is currently one of the busiest in the nation and utilizes a novel multimodality (MRI, fMRI, MEG) imaging approach to seizure lateralization and localization that aims to improve surgical outcome. The multimodality (MRI, fMRI, MEG) epilepsy imaging teams (Drs. Rose, Xiang, Vannest) also have active research programs focused using non-invasive imaging to better understand the interaction between epileptic seizures, brain development and brain activity. The basic neuroscience component of the epilepsy program focuses on determining the functional significance of the genetic variations found in the clinical pharmacogenetic studies (Dr. Holland) along with developing non-genetic biomarkers of epilepsy and response to therapy (Dr. Hallinan).

Tuberous Sclerosis

In the past year I have seen enhancement and extension of various research programs related to Tuberous Sclerosis Clinic. A trial of RAD-001 in giant cell astrocytomas has almost completed enrollment and shows great promise for reduction in tumor volume as well as improvement in seizures and cognition. The trial is to continue with RAD-001 for renal angiomyolipomas as well as with rapamycin for lymphangioleiomyomatosis and angiomyolipomas. The addition of Darcy Krueger, MD, PhD has enhanced our basic science program. In cooperation with Dr. George Thomas and Sara Kozma at Genome Research Institute. Dr. Krueger is performing basic science research on the role of mTOR in cognition and motor development. An NIH grant was submitted to fund CCHMC involvement in an infantile spasms consortium. The key aspect to this will be an evaluation of the efficacy of RAD-001 for infantile spasms, first in tuberous sclerosis patients, and later in infantile spasms for other causes. Novartis has agreed to fund the performance of a trial of RAD-001 in infantile spasms and tuberous sclerosis patients. A clinical trial is being planned for intractable epilepsy and tuberous sclerosis and cortical dysplasia using RAD-001 in collaboration with Baylor University College of Medicine.

Our Tuberous Sclerosis Clinic remains the largest in the United States following over 500 adults and children with the disorder. We have improved and extended services to individuals with tuberous sclerosis through educational programs, community support, and the first ever camp for tuberous sclerosis children. Our clinic remains the only true and multidisciplinary Tuberous Sclerosis Clinic with access to full range of medical care for both adults and children with the disorder.

The Headache Center

The Headache Center at Cincinnati Children’s Hospital Medical Center, Department of Neurology, was established in the fall of 1996. The Headache Center was organized as a multi-disciplinary clinic combining Child Neurologist, Child Psychologist and Nurse Practitioners to diagnose and treat children with headache disorders. It is based within a growing academically and clinically based neurology department at Cincinnati's Children's Hospital Medical Center, and is affiliated with the University of Cincinnati College of Medicine and the Division of Psychology at CCHMC. Over the past 10 years, we have seen nearly 4000 children with the complaint of headaches. A clinical diagnosis and a standardized diagnosis using the International Classification of Headache Disorders, 2nd Edition, are also made for each of these children. A detailed questionnaire about the child’s headache has been developed and a computer-based database to accumulate medical information as well as response rate was designed and is continually updated. Treatment strategies include acute therapy for individual headache episodes, prophylactic therapy for preventing headache episodes and psychological intervention including biofeedback-assisted relaxation training as well as life style behavior adjustments. This multidisciplinary approach has been demonstrated to be highly effective, not only in the standard methods of measuring outcome, but also in using tools developed and validated at CCHMC to characterize disability and quality of life. The Headache Center has also been designed to develop and expand research into childhood headache disorders by examining new treatment options, improved characterization of childhood headache and response patterns, and understanding the genetic pathophysiology of childhood headaches. In this role, multiple studies and publications have been developed including one of the few NIH sponsored studies in headache examining genomic expression patterns, as well as an NIH sponsored study on treatment of chronic daily headache with combined pharmacologic and behavioral treatment. Education is also a key component with the Headache Center established the first pediatric fellowship for the study of childhood headaches in the country, the only pediatric headache fellowships out of the 1 established headache fellowships in the country certified by the United Council of Neurologic Subspecialties with both Drs. Hershey and Kabbouche board certified in Headache Medicine.

Significant Publications in FY08

Bissler, JJ etal, Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleimomyomatosis, N.Engl. J. Med. 2008, 358: 140-151

This is the second report from our group of a new treatment for patients with tuberous sclerosis. This shows that mTOR inhibition works for angiomyolipoma. The previous report showed the same results for brain tumors in this condition.

Holland, KD etal, Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial epilepsy, Neurosci. Lett. 2008, 433: 65-70

First report on SCN3A mutation as likely cause of epilepsy in this patient

Tillema, JM etal, Cortical reorganization of language functioning following perinatal left MCA stroke, Brain Lang. 2008, 105: 99-111

Clear evidence of plasticity of the neonatal brain for language function after perinatal stroke.

 

Division Highlights

Movement Disorders

The Transcranial Magnetic Stimulation Laboratory - We continue to study motor cortex physiology in Tourette Syndrome and ADHD and have performed pioneering studies of the relationship between dopamine transporter genotype variations and physiological responses to dopaminergic and noradrenergic medications.  See publications list.  We also are co-investigators in a two-site, five year study, the first NIH funded study to combine TMS and fMRI to assess motor cortex and motor function in ADHD, with ongoing recruitment.  We have recently purchased equipment which could allow for an exciting new venture in quantifying long term potentiation and depression in vivo in humans, using TMS, and have submitted a grant proposal to use this for Tuberous Sclerosis Complex. 

Movement Disorders

Tourette Syndrome Genetics - We are one of two sites in a  5-year NIH-funded study to identify the prevalence of SLITRK1 mutations and other mutations in TS.  Another NIH grant is in the planning phases.

Neurology Basic Science Labs

The Division officially launched the Animal Behavioral Phenotyping Core this past year under the direction of Drs. Vorhees and Williams (Website: http://www.cincinnatichildrens.org/research/cores/abc/default.htm). This is a new collaborative research facility available to investigators from all divisions of CCRF, any department of UC, and outside institutions. The new core has already secured multiple CCRF and UC collaborators, one outside contract with a major pharmaceutical company, and has a pending contract with a start-up pharmaceutical company. The core specializes in the characterization of transgenic mice, but can also evaluate rats. The new core offers a wide range of behavioral assays for both species, many more than most comparable facilities at other universities. A new laboratory to expand the core’s testing capacity will begin construction in the near future.

Neurology Basic Science Labs

New Animal Model of Methamphetamine-induced Cognitive Impairment - Over the course of the last 10-15 years there has emerged clear evidence that methamphetamine (Meth) abusers, especially chronic users, develop cognitive impairments that remain long after these individuals enter treatment and even after they have been abstinent for 6 months, a year, or even longer. Attention, learning, and memory deficits have been reported in many studies of former chronic users. For 5-10 years, animal models of this problem have been under investigation as a means to understand these effects, uncover the mechanisms of action, and to use these models to develop interventions to treat these impairments. Meth is neurotoxic at high doses in humans and rodents. Unfortunately, in rodents few learning and memory effects have been found even after neurotoxic doses are given. The best model until now has been Meth-induced novel object memory impairments in rats. Recently, the reliability of this model has come into question. During the past year, the laboratories of Drs. Williams and Vorhees have found a new cognitive effect from high dose Meth treatment in the form of impairments in path integration (also called egocentric) learning. The effect has been replicated using different Meth dosing schedules and is both reliable and substantial. Further, the effect on the HPA axis was tested in sham versus adrenalectomized Meth or Saline treated rats and the impairment was unchanged. This proved that Meth-induced corticosterone release does not contribute to the learning impairment. Drs. Williams and Vorhees recently submitted a new grant application to NIH to perfect the model, expand its utility, test potential mechanisms of action in relation to neurotransmitters (dopamine, serotonin, and glutamate), and to test a potentially promising treatment to reverse the damage after it has occurred using a drug already marketed.

MEG Research

We have completed a study on high-frequency neuromagnetic signals in the developing brain. To our knowledge, this is the world's first high-frequency MEG database from healthy children. The database lays a foundation for identification of brain abnormality and functional developmental delay in children.  primary clinical application and research interests are 1) determination of the seizure onset location in children with medically intractable epilepsy who are candidates for surgery and 2) localization of the normal functional brain regions subserving language and motor control so that these regions are preserved during epilepsy surgery. There are multiple methods for localization of abnormal and normal brain function with MEG; however, only a few sites worldwide study children with MEG. The optimum methods are not yet known for localization of the epileptic focus and normal brain function in children. Dr. Rose has just received approval for an IRB protocol: Algorithms for Improved Interpretation of Electromagnetic Brain Activity to evaluate and optimize these MEG methodologies for children. He is collaborating with researchers at the University of Cincinnati, Miami University, and Oakland University in these pursuits. A second research interest is in the synergistic value of comparing findings across multiple modalities (MEG, fMRI, SPECT, PET). Dr. Rose has been developing collaborations principally with CCHMC Department of Radiology in pursuit of these research goals. Dr. Rose is also collaborating with multiple colleagues within the Neurology Division on brain research using MEG and also EEG. 

Division Collaboration

Collaboration with Division of Human Genetics

Collaborating Faculty: Greg Grabowski, MD ; Ying Sun, PhD

Collaborating on mouse knock-out models of lipid storage disease

Collaboration with Division of Anesthesiology

Collaborating Faculty: Steve Danzer, PhD

Collaborating on the dentate gyrus-specific floxed pten knock-out mouse model of autism with hypothesized increased seizure susceptibility

Collaboration with Imaging Research Center

Collaborating Faculty: Weihong Yuan, PhD; Scott Holland, PhD

Collaborating on a model of early onset hydrocephalus and the beneficial effects of shung surgery on cognitive and behavioral outcome in rats

Collaboration with Division of Anesthesiology

Collaborating Faculty: John McAuliffe, MD

Effects of early hypoxia-ischemia and anesthetics on cognitive outcome in mice

Collaboration with Division of Anesthesiology

Collaborating Faculty: Andreas Lepke, MD

Effects of early anesthesia exposure on apoptosis and cognitive development

Collaboration with Division of Allergy & Immunology

Collaborating Faculty: Marc Rothenberg, MD, PhD

Effects of NPS and its putative receptor GPRA in asthma and CNS function

Return to Top
Loading...

Division Publications

  1. Newmeyer A, deGrauw T, Clark J, Chuck G, Salomons G. Screening of male patients with autism spectrum disorder for creatine transporter deficiency. Neuropediatrics. 2007; 38: 310-2.
  2. Newmeyer AJ, Grether S, Grasha C, White J, Akers R, Aylward C, Ishikawa K, Degrauw T. Fine motor function and oral-motor imitation skills in preschool-age children with speech-sound disorders. Clin Pediatr (Phila). 2007; 46: 604-11.
  3. Rosenberg EH, Martinez Munoz C, Betsalel OT, van Dooren SJ, Fernandez M, Jakobs C, deGrauw TJ, Kleefstra T, Schwartz CE, Salomons GS. Functional characterization of missense variants in the creatine transporter gene (SLC6A8): improved diagnostic application. Hum Mutat. 2007; 28: 890-6.
  4. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008; 358: 140-51.
  5. Ma L, Teruya-Feldstein J, Bonner P, Bernardi R, Franz DN, Witte D, Cordon-Cardo C, Pandolfi PP. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res. 2007; 67: 7106-12.
  6. Madhavan D, Schaffer S, Yankovsky A, Arzimanoglou A, Renaldo F, Zaroff CM, LaJoie J, Weiner HL, Andermann E, Franz DN, Leonard J, Connolly M, Cascino GD, Devinsky O. Surgical outcome in tuberous sclerosis complex: a multicenter survey. Epilepsia. 2007; 48: 1625-8.
  7. Gilbert DL, Zhang J, Lipps TD, Natarajan N, Brandyberry J, Wang Z, Sallee FR, Wassermann EM. Atomoxetine treatment of ADHD in Tourette syndrome: reduction in motor cortex inhibition correlates with clinical improvement. Clin Neurophysiol. 2007; 118: 1835-41.
  8. Lit L, Gilbert DL, Walker W, Sharp FR. A subgroup of Tourette's patients overexpress specific natural killer cell genes in blood: a preliminary report. Am J Med Genet B Neuropsychiatr Genet. 2007; 144B: 958-63.
  9. Spencer TJ, Sallee FR, Gilbert DL, Dunn DW, McCracken JT, Coffey BJ, Budman CL, Ricardi RK, Leonard HL, Allen AJ, Milton DR, Feldman PD, Kelsey DK, Geller DA, Linder SL, Lewis DW, Winner PK, Kurlan RM, Mintz M. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord. 2008; 11: 470-81.
  10. Baker GA, Hargis E, Hsih MM, Mounfield H, Arzimanoglou A, Glauser T, Pellock J, Lund S. Perceived impact of epilepsy in teenagers and young adults: an international survey. Epilepsy Behav. 2008; 12: 395-401.
  11. de los Reyes EC, McJunkin JE, Glauser TA, Tomsho M, O'Neal J. Periodic lateralized epileptiform discharges in La Crosse encephalitis, a worrisome subgroup: clinical presentation, electroencephalogram (EEG) patterns, and long-term neurologic outcome. J Child Neurol. 2008; 23: 167-72.
  12. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008; 70: 1950-8.
  13. Grace CE, Schaefer TL, Herring NR, Skelton MR, McCrea AE, Vorhees CV, Williams MT. (+)-Methamphetamine increases corticosterone in plasma and BDNF in brain more than forced swim or isolation in neonatal rats. Synapse. 2008; 62: 110-21.
  14. Hershey AD. Genetics of migraine headache in children. Curr Pain Headache Rep. 2007; 11: 390-5.
  15. Hershey AD, Winner P, Kabbouche MA, Powers SW. Headaches. Curr Opin Pediatr. 2007; 19: 663-9.
  16. Lewis DW, Winner P, Hershey AD, Wasiewski WW. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics. 2007; 120: 390-6.
  17. Winner P, Hershey AD. Epidemiology and diagnosis of migraine in children. Curr Pain Headache Rep. 2007; 11: 375-82.
  18. Holland KD, Glauser TA. Response to carbamazepine in children with newly diagnosed partial onset epilepsy. Neurology. 2007; 69: 596-9.
  19. Holland KD, Kearney JA, Glauser TA, Buck G, Keddache M, Blankston JR, Glaaser IW, Kass RS, Meisler MH. Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial epilepsy. Neurosci Lett. 2008; 433: 65-70.
  20. Lachhwani DK, Loddenkemper T, Holland KD, Kotagal P, Mascha E, Bingaman W, Wyllie E. Discontinuation of medications after successful epilepsy surgery in children. Pediatr Neurol. 2008; 38: 340-4.
  21. Gilman DK, Palermo TM, Kabbouche MA, Hershey AD, Powers SW. Primary headache and sleep disturbances in adolescents. Headache. 2007; 47: 1189-94.
  22. Korostenskaja M, Kicic D, Kahkonen S. The effect of methylphenidate on auditory information processing in healthy volunteers: a combined EEG/MEG study. Psychopharmacology (Berl). 2008; 197: 475-86.
  23. Krueger DA, Franz DN. Current management of tuberous sclerosis complex. Paediatr Drugs. 2008; 10: 299-313.
  24. Modi AC, Morita DA, Glauser TA. One-month adherence in children with new-onset epilepsy: white-coat compliance does not occur. Pediatrics. 2008; 121: e961-6.
  25. Spitzmiller RE, Phillips T, Meinzen-Derr J, Hoath SB. Amplitude-integrated EEG is useful in predicting neurodevelopmental outcome in full-term infants with hypoxic-ischemic encephalopathy: a meta-analysis. J Child Neurol. 2007; 22: 1069-78.
  26. Herring NR, Schaefer TL, Tang PH, Skelton MR, Lucot JP, Gudelsky GA, Vorhees CV, Williams MT. Comparison of time-dependent effects of (+)-methamphetamine or forced swim on monoamines, corticosterone, glucose, creatine, and creatinine in rats. BMC Neurosci. 2008; 9: 49.
  27. Schaefer TL, Skelton MR, Herring NR, Gudelsky GA, Vorhees CV, Williams MT. Short- and long-term effects of (+)-methamphetamine and (+/-)-3,4-methylenedioxymethamphetamine on monoamine and corticosterone levels in the neonatal rat following multiple days of treatment. J Neurochem. 2008; 104: 1674-85.
  28. Miles MV, Patterson BJ, Chalfonte-Evans ML, Horn PS, Hickey FJ, Schapiro MB, Steele PE, Tang PH, Hotze SL. Coenzyme Q10 (ubiquinol-10) supplementation improves oxidative imbalance in children with trisomy 21. Pediatr Neurol. 2007; 37: 398-403.
  29. Skelton MR, Williams MT, Schaefer TL, Vorhees CV. Neonatal (+)-methamphetamine increases brain derived neurotrophic factor, but not nerve growth factor, during treatment and results in long-term spatial learning deficits. Psychoneuroendocrinology. 2007; 32: 734-45.
  30. Skelton MR, Williams MT, Vorhees CV. Developmental effects of 3,4-methylenedioxymethamphetamine: a review. Behav Pharmacol. 2008; 19: 91-111.
  31. Tillema JM, Byars AW, Jacola LM, Schapiro MB, Schmithorst VJ, Szaflarski JP, Holland SK. Cortical reorganization of language functioning following perinatal left MCA stroke. Brain Lang. 2008; 105: 99-111.
  32. Holland SK, Vannest J, Mecoli M, Jacola LM, Tillema JM, Karunanayaka PR, Schmithorst VJ, Yuan W, Plante E, Byars AW. Functional MRI of language lateralization during development in children. Int J Audiol. 2007; 46: 533-51.
  33. Vannest J, Szaflarski JP, Privitera MD, Schefft BK, Holland SK. Medial temporal fMRI activation reflects memory lateralization and memory performance in patients with epilepsy. Epilepsy Behav. 2008; 12: 410-8.
  34. McAuliffe JJ, Joseph B, Hughes E, Miles L, Vorhees CV. Metallothionein I,II deficient mice do not exhibit significantly worse long-term behavioral outcomes following neonatal hypoxia-ischemia: MT-I,II deficient mice have inherent behavioral impairments. Brain Res. 2008; 1190: 175-85.
  35. Pan D, Sciascia A, 2nd, Vorhees CV, Williams MT. Progression of multiple behavioral deficits with various ages of onset in a murine model of Hurler syndrome. Brain Res. 2008; 1188: 241-53.
  36. Siuciak JA, McCarthy SA, Chapin DS, Reed TM, Vorhees CV, Repaske DR. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme. Neuropharmacology. 2007; 53: 113-24.
  37. Vorhees CV, Schaefer TL, Williams MT. Developmental effects of +/-3,4-methylenedioxymethamphetamine on spatial versus path integration learning: effects of dose distribution. Synapse. 2007; 61: 488-99.
  38. Vorhees CV, Skelton MR, Williams MT. Age-dependent effects of neonatal methamphetamine exposure on spatial learning. Behav Pharmacol. 2007; 18: 549-62.
  39. Lingrel JB, Williams MT, Vorhees CV, Moseley AE. Na,K-ATPase and the role of alpha isoforms in behavior. J Bioenerg Biomembr. 2007; 39: 385-9.
  40. Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord. 2008; 18: 365-70.
  41. Miles MV, Miles L, Tang PH, Horn PS, Steele PE, DeGrauw AJ, Wong BL, Bove KE. Systematic evaluation of muscle coenzyme Q10 content in children with mitochondrial respiratory chain enzyme deficiencies. Mitochondrion. 2008; 8: 170-80.
  42. Wu SW, Graham B, Gelfand MJ, Gruppo RE, Dinopolous A, Gilbert DL. Clinical and positron emission tomography findings of chorea associated with primary antiphospholipid antibody syndrome. Mov Disord. 2007; 22: 1813-5.
  43. Liu Y, Xiang J, Wang Y, Vannest JJ, Byars AW, Rose DF. Spatial and frequency differences of neuromagnetic activities in processing concrete and abstract words. Brain Topogr. 2008; 20: 123-9.
Return to Top
Loading...

Grants, Contracts, and Industry Agreements

Grant and Contract Awards Annual Direct / Project Period Direct

Degrauw, A

Phase 3 Trial of Coenzyme Q10 in Mitochondrial Diseases
R01 FD 00303209/20/06 - 05/31/08 $54,932 / $108,933
Point Care Center for Emerging Neurotechnologies
U54 EB 00795409/30/07 - 06/30/12 $6,881 / $37,271

Gilbert, D

Anomalous Motor Physiology In ADHD
R01 MH 07816007/01/06 - 06/30/11 $60,525 / $318,246
The Role of SLITRK1 in Tourette and Related Disorders
R01 NS 05627609/01/06 - 08/31/11 $25,030 / $134,949

Glauser, T

Childhood Absence Epilepsy: RX, PK-PD-Pharmacogenetics
U01 NS 04591109/30/03 - 10/31/08 $5,512,280 / $14,846,498
Epilepsy Phenome/Genome Project
R01 NL 05399805/01/07 - 04/30/12 $14,898 / $74,490

Hallinan, B

Predictive Potential of CSF Steroid Profile in Infants
10/01/06 - 09/30/08 $15,855 / $23,465

Vannest, J

The Neural Basis of Language In Neurodevelopmental Disorders
07/01/07 - 06/28/09 $9,458 / $18,916

Vorhees, C

Genetic Differences in PCB-Induced Behavior
R21 ES 01533512/15/07 - 11/30/09 $60,600 / $80,127
Developmental Effects of Methamphetamine-Like Stimulants
R01 DA 00673304/01/05 - 03/31/10 $185,843 / $1,000,000
Effects of Neonatal MDMA on Brain and Behavior
R01 DA 02139404/01/06 - 03/31/11 $190,316 / $1,000,000
Training Program in Teratology
T32 ES 00705107/01/07 - 06/30/12 $286,170 / $1,432,850

Williams, M.

Effect of Lead, Manganese and Stress During Development
R01 ES 01568909/18/06 - 06/30/11 $242,750 / $1,250,000

Wong, B.

Translational Research in Dystrophinopathies
R01 NS 04326404/01/06 - 03/31/11 $12,981 / $78,663
Current Year Direct$6,678,519
Industry Contracts

Franz, D

$ 68,056

Hershey, A

$ 1,925

Kabbouche, M

$ 3,696

Vorhees, C

$ 159,652

Wong, B

$ 53,497
Current Year Direct Receipts$286,826
Total$6,965,345
Return to Top
Loading...